Gastrointestinal
Also called SBS, Short Gut Syndrome
Short Bowel Syndrome results from loss of sufficient small intestinal length or function, typically defined as less than 150-200 cm of functioning small bowel (normal is 300-600 cm). The loss of absorptive surface area leads to malabsorption of water, electrolytes, nutrients, and medications.
Short Bowel Syndrome results from surgical resection (most commonly due to Crohn's disease, mesenteric ischemia, trauma, or surgical complications) or congenital conditions. It can develop at any age, in both children and adults. In children, congenital short bowel from small intestinal atresia or gastroschisis is the primary cause. In adults, disease-related resection (Crohn's disease) or vascular events (mesenteric infarction) predominate. Long-term outcomes depend on the length and location of remaining bowel.
Clinical trials for Short Bowel Syndrome focus on promoting intestinal adaptation and reducing parenteral nutrition dependence. Growth hormone therapy, glutamine supplementation, and pharmacologic agents have shown benefits. Trials investigate teduglutide (glucagon-like peptide 2 analog), which has FDA approval and promotes intestinal mucosal growth. Newer approaches including stem cell therapy and intestinal transplantation are being refined. Management requires coordination with specialized centers experienced in parenteral nutrition and Short Bowel Syndrome. Patients should consult with gastroenterologists specializing in this condition.
Eosinophilic Esophagitis is a rare allergic/immune-mediated inflammatory disease of the esophagus characterized by eosin...
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease in which the immune system mistakenly attacks th...
Autoimmune Hepatitis (AIH) is a chronic liver disease characterized by persistent inflammation and progressive fibrosis ...